The Ministry of Health, Labor, and Welfare (MHLW) has selected a total of seven compounds as part of its support for projects for the commercialization of COVID-19 treatments. The MHLW will bankroll up to 2 billion yen per project in…
To read the full story
Related Article
- MHLW to Fund Avigan Program, COVID-19 Drugs from AZ, Shionogi
September 8, 2021
REGULATORY
- War-Linked Supply Concerns Rise to 43 Cases, Focus Shifts to Solvents, Packaging
April 24, 2026
- JPMA Pushes for “Freeze” on On-Patent Drug Price Cuts at LDP Meeting
April 23, 2026
- MHLW to Exclude High School-Age and Younger from OTC-Like Drug Charge: Official
April 23, 2026
- Japan, Singapore to Share GMP Inspection Results under Cooperation Pact
April 23, 2026
- MHLW Orders Label Revisions for Remicade, Enbrel, Bavencio, and More Drugs
April 22, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





